Wenying Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Wenying Zhang has a total of 208 co-authors. Here are the top co-authors by number of shared publications:
D. Brian Dawson
3 shared publications- Ammar Husami
Cincinnati Childrens Hospital Medical Center, Falmouth, Kentucky, United States
2 shared publications Jack Bleesing
Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, USA
2 shared publicationsJie Liu
Cincinnati Childrens Hosp, Med Ctr, Div Human Genet, Cincinnati, OH 45229 USA
2 shared publications- Monica Driscoll
Rutgers the State University of New Jersey
2 shared publications Qiaoning Guan
Cincinnati Childrens Hosp, Med Ctr, Div Human Genet, Cincinnati, OH 45229 USA
2 shared publications
Latest Publications
- Open Access
- 16 November 2026
- Published by American Society of Hematology in Blood
Regenerative Stress Contributes to Higher Clonal Hematopoiesis with Myelodysplastic Features in Sickle Cell Disease Mice
Sickle cell disease (SCD) affects millions globally, causing significant lifelong morbidity and early death. As childhood mortality is reduced and SCD patients are surviving to adulthood, increased risk of hematological malignancy (HM) is becoming evident. Risk of therapy-related myelodysplastic syndrome (MDS)/acute myeloid leukemia, following gene therapy or hematopoietic stem cell transplant (HSCT) is also higher in SCD. The specific pathobiology that predisposes to HM is necessary to address, since survival has improved and gene therapy and HSCT are being increasingly used. We modelled the increased risk of HM in humanized SCD mice, compared to age-, sex- and strain-matched normal counterparts. We serially monitored hematopoiesis in blood and bone marrow up to 1-year-of-age and performed highly sensitive, error-corrected deep sequencing of 450 MDS/HM-associated genes. Unlike controls, SCD mice showed an 'ageing-like' phenotype with premature development of myeloid-biased hematopoiesis and hematopoietic stem/progenitor cells (HSPC) mutational profile characteristic of aged mice/humans. Furthermore, a high proportion of SCD mice developed hematopoiesis with dysplastic features reminiscent of MDS morphology and higher clonal hematopoiesis burden. Imposition of regenerative stress by serial HSCT further increased HSPC mutational burden, resulting in evolution/expansion of clones harboring oncogenic driver mutations. Our study indicates that increased HSC regenerative stress, imposed either by chronic erythropoietic demand or via autologous HSCT in SCD increases the risk of developing clonal hematopoiesis and MDS-like features. Our study provides insights into a mechanism underlying increased risk of HM in this non-malignant hematological disorder, and suggests that early intervention with curative therapies may circumvent this risk.
- 16 November 2026
- Published by American Society of Hematology in Blood
Open AccessRegenerative Stress Contributes to Higher Clonal Hematopoiesis with Myelodysplastic Features in Sickle Cell Disease Mice
Sickle cell disease (SCD) affects millions globally, causing significant lifelong morbidity and early death. As childhood mortality is reduced and SCD patients are surviving to adulthood, increased risk of hematological malignancy (HM) is becoming evident. Risk of therapy-related myelodysplastic syndrome (MDS)/acute myeloid leukemia, following gene therapy or hematopoietic stem cell transplant (HSCT) is also higher in SCD. The specific pathobiology that predisposes to HM is necessary to address, since survival has improved and gene therapy and HSCT are being increasingly used. We modelled the increased risk of HM in humanized SCD mice, compared to age-, sex- and strain-matched normal counterparts. We serially monitored hematopoiesis in blood and bone marrow up to 1-year-of-age and performed highly sensitive, error-corrected deep sequencing of 450 MDS/HM-associated genes. Unlike controls, SCD mice showed an 'ageing-like' phenotype with premature development of myeloid-biased hematopoiesis and hematopoietic stem/progenitor cells (HSPC) mutational profile characteristic of aged mice/humans. Furthermore, a high proportion of SCD mice developed hematopoiesis with dysplastic features reminiscent of MDS morphology and higher clonal hematopoiesis burden. Imposition of regenerative stress by serial HSCT further increased HSPC mutational burden, resulting in evolution/expansion of clones harboring oncogenic driver mutations. Our study indicates that increased HSC regenerative stress, imposed either by chronic erythropoietic demand or via autologous HSCT in SCD increases the risk of developing clonal hematopoiesis and MDS-like features. Our study provides insights into a mechanism underlying increased risk of HM in this non-malignant hematological disorder, and suggests that early intervention with curative therapies may circumvent this risk.
- Open Access
- 15 November 2026
- Published by MDPI AG in Brain Sciences
- Vol. 16 (11) , 1249
Genetic Evaluation of Intracranial Arterial Aneurysms in Pediatric Practice: A Pragmatic Approach for the Clinician
Intracranial arterial aneurysm (IAA) is an important cause of hemorrhagic stroke in children and presents a unique diagnostic challenge for the clinician. Exhibiting failure of arterial wall integrity decades before the general population, this early and aggressive arteriopathy suggests intrinsic susceptibility to disease. This narrative review summarizes the literature on IAA genetics, highlighting monogenetic causes, known risk alleles from population-based analyses, and opportunities to expand the literature on childhood disease. Clinical findings that may lead to suspicion for genetic arteriopathy are discussed—highlighting connective tissue disorder phenotypes, family history of arteriopathy, and radiographic characteristics unique to childhood IAA. The common clinical genetic diagnostics—targeted gene panels, whole exome sequencing, whole genome sequencing, and advanced testing modalities—are detailed with attention to their use in IAA in children and adults. Given the ever-expanding palette of genetic testing platforms, the busy clinician may find test selection daunting and access to genetic professionals rare. To help with this selection, we provide a pragmatic guide to test selection and analysis of genetic testing in childhood IAA.
- 15 November 2026
- Published by MDPI AG in Brain Sciences
- Vol. 16 (11) , 1249
Open AccessGenetic Evaluation of Intracranial Arterial Aneurysms in Pediatric Practice: A Pragmatic Approach for the Clinician
Intracranial arterial aneurysm (IAA) is an important cause of hemorrhagic stroke in children and presents a unique diagnostic challenge for the clinician. Exhibiting failure of arterial wall integrity decades before the general population, this early and aggressive arteriopathy suggests intrinsic susceptibility to disease. This narrative review summarizes the literature on IAA genetics, highlighting monogenetic causes, known risk alleles from population-based analyses, and opportunities to expand the literature on childhood disease. Clinical findings that may lead to suspicion for genetic arteriopathy are discussed—highlighting connective tissue disorder phenotypes, family history of arteriopathy, and radiographic characteristics unique to childhood IAA. The common clinical genetic diagnostics—targeted gene panels, whole exome sequencing, whole genome sequencing, and advanced testing modalities—are detailed with attention to their use in IAA in children and adults. Given the ever-expanding palette of genetic testing platforms, the busy clinician may find test selection daunting and access to genetic professionals rare. To help with this selection, we provide a pragmatic guide to test selection and analysis of genetic testing in childhood IAA.
- Open Access
- 24 August 2026
- Published by Springer Nature in Journal of Clinical Immunology
Diagnostic Utility of FAS Sequencing in Suspected ALPS: Insights from a Large Clinical Cohort
Autoimmune lymphoproliferative syndrome (ALPS) is a rare immune dysregulation disorder most commonly caused by defects in the FAS-mediated apoptosis pathway. While germline FAS variants account for the majority of cases, somatic variants, typically restricted to double-negative T cells (DNTCs), may be under-detected in routine testing. We retrospectively analyzed FAS full-gene sequencing in 686 probands and 3 family members with suspected ALPS to assess diagnostic yield, variant spectrum, and clinical utility. Germline FAS variants were identified in 73/685 probands (10.7%) using whole blood or cytobrush samples. Somatic FAS variants were detected in 8/22 cases (36.4%) using sorted DNTCs, demonstrating a substantially higher diagnostic yield in patients with strong clinical suspicion but negative germline testing. A total of 65 unique diagnostic sequencing variants were identified, of which 49% were previously unreported. Variants were enriched in the intracellular domain (65%), with most disrupting the death domain. Three cases with copy number variants (CNVs) were identified, including deletions spanning intron 5 to exon 9, intron 6 to exon 9, and a partial exon 9 deletion involving the C-terminal region of FAS , expanding the known spectrum of structural variants. One case demonstrated a somatic FAS variant with a markedly higher level than wild-type allele in DNTCs, consistent with somatic loss of heterozygosity (sLOH), representing the second reported case of ALPS-sFAS/sLOH. These findings highlight the importance of comprehensive FAS testing, including germline and somatic analysis with DNTC-based sequencing and CNV detection, to improve diagnostic accuracy and inform clinical management in suspected ALPS.
- 24 August 2026
- Published by Springer Nature in Journal of Clinical Immunology
Open AccessDiagnostic Utility of FAS Sequencing in Suspected ALPS: Insights from a Large Clinical Cohort
Autoimmune lymphoproliferative syndrome (ALPS) is a rare immune dysregulation disorder most commonly caused by defects in the FAS-mediated apoptosis pathway. While germline FAS variants account for the majority of cases, somatic variants, typically restricted to double-negative T cells (DNTCs), may be under-detected in routine testing. We retrospectively analyzed FAS full-gene sequencing in 686 probands and 3 family members with suspected ALPS to assess diagnostic yield, variant spectrum, and clinical utility. Germline FAS variants were identified in 73/685 probands (10.7%) using whole blood or cytobrush samples. Somatic FAS variants were detected in 8/22 cases (36.4%) using sorted DNTCs, demonstrating a substantially higher diagnostic yield in patients with strong clinical suspicion but negative germline testing. A total of 65 unique diagnostic sequencing variants were identified, of which 49% were previously unreported. Variants were enriched in the intracellular domain (65%), with most disrupting the death domain. Three cases with copy number variants (CNVs) were identified, including deletions spanning intron 5 to exon 9, intron 6 to exon 9, and a partial exon 9 deletion involving the C-terminal region of FAS , expanding the known spectrum of structural variants. One case demonstrated a somatic FAS variant with a markedly higher level than wild-type allele in DNTCs, consistent with somatic loss of heterozygosity (sLOH), representing the second reported case of ALPS-sFAS/sLOH. These findings highlight the importance of comprehensive FAS testing, including germline and somatic analysis with DNTC-based sequencing and CNV detection, to improve diagnostic accuracy and inform clinical management in suspected ALPS.
- 16 July 2026
- Published by Elsevier in Cancer Genetics
- Vol. 306-307, 232-236
Discordant neoplasms in monozygotic twins with a germline RECQL5 variant
- 16 July 2026
- Published by Elsevier in Cancer Genetics
- Vol. 306-307, 232-236
Discordant neoplasms in monozygotic twins with a germline RECQL5 variant
- Open Access
- 12 March 2026
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 10 (2)
Molecular diagnosis of inherited platelet disorder via a targeted whole-exome virtual gene panel: a 5-year institutional experience
- 12 March 2026
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 10 (2)
Open AccessMolecular diagnosis of inherited platelet disorder via a targeted whole-exome virtual gene panel: a 5-year institutional experience
- Open Access
A De Novo Loss-of-Function NCKAP1 Variant in a Boy with Neurodevelopmental Delay and Congenital Heart Defect
Background: Neurodevelopmental disorders (NDDs), such as autism spectrum disorder (ASD), intellectual disability (ID), and global developmental delay (GDD), frequently have underlying genetic causes. NCKAP1, a gene essential for actin cytoskeleton remodeling and neuronal development, has recently gained recognition as a promising candidate gene in NDDs. While not yet linked to a defined Mendelian disorder, damaging NCKAP1 variants have been identified in individuals with NDDs. NCKAP1 is also expressed in cardiac tissue, with emerging evidence supporting its potential involvement in cardiac development. Here, we present a case of a patient with neurodevelopmental delay and congenital heart disease (CHD) harboring a novel damaging NCKAP1 variant. Methods: Comprehensive clinical evaluations and trio exome sequencing (proband and parents) were conducted on a patient with complex cardiac and neurodevelopmental phenotypes. Results: We identified a de novo heterozygous frameshift variant in NCKAP1, NM_205842.3:c.2956_2959del p.(Ser986Hisfs*34), predicted to result in loss of function through nonsense-mediated mRNA decay. The patient’s clinical features included neonatally diagnosed and surgically repaired infradiaphragmatic total anomalous pulmonary venous return (TAPVR), intellectual disability, speech delay, and autistic traits. His NDD phenotypes and variant type align well with previously described NCKAP1-associated NDD, while the cardiac anomaly adds evidence to the gene’s expanding phenotypic spectrum. This represents the fourth reported case linking NCKAP1 variants to CHD and/or neurodevelopmental delay. Conclusions: This case strengthens the growing recognition of NCKAP1 in both neurodevelopment and cardiac formation. It highlights the importance of genetic testing for individuals with overlapping developmental and cardiac conditions. Further research is warranted to elucidate the role of NCKAP1 in cardiac development and its contribution to CHD.
Open AccessA De Novo Loss-of-Function NCKAP1 Variant in a Boy with Neurodevelopmental Delay and Congenital Heart Defect
Background: Neurodevelopmental disorders (NDDs), such as autism spectrum disorder (ASD), intellectual disability (ID), and global developmental delay (GDD), frequently have underlying genetic causes. NCKAP1, a gene essential for actin cytoskeleton remodeling and neuronal development, has recently gained recognition as a promising candidate gene in NDDs. While not yet linked to a defined Mendelian disorder, damaging NCKAP1 variants have been identified in individuals with NDDs. NCKAP1 is also expressed in cardiac tissue, with emerging evidence supporting its potential involvement in cardiac development. Here, we present a case of a patient with neurodevelopmental delay and congenital heart disease (CHD) harboring a novel damaging NCKAP1 variant. Methods: Comprehensive clinical evaluations and trio exome sequencing (proband and parents) were conducted on a patient with complex cardiac and neurodevelopmental phenotypes. Results: We identified a de novo heterozygous frameshift variant in NCKAP1, NM_205842.3:c.2956_2959del p.(Ser986Hisfs*34), predicted to result in loss of function through nonsense-mediated mRNA decay. The patient’s clinical features included neonatally diagnosed and surgically repaired infradiaphragmatic total anomalous pulmonary venous return (TAPVR), intellectual disability, speech delay, and autistic traits. His NDD phenotypes and variant type align well with previously described NCKAP1-associated NDD, while the cardiac anomaly adds evidence to the gene’s expanding phenotypic spectrum. This represents the fourth reported case linking NCKAP1 variants to CHD and/or neurodevelopmental delay. Conclusions: This case strengthens the growing recognition of NCKAP1 in both neurodevelopment and cardiac formation. It highlights the importance of genetic testing for individuals with overlapping developmental and cardiac conditions. Further research is warranted to elucidate the role of NCKAP1 in cardiac development and its contribution to CHD.
- Open Access
- 19 June 2025
- Published by American Society of Hematology in Blood
- Vol. 145 (25) , 2992-3006
Beyond genotype: challenges in predicting disease risk for carriers of biallelic perforin variants
Genetic screening for severe congenital immunohematological diseases offers potential for early intervention, particularly through preemptive allogeneic hematopoietic stem cell transplantation (HSCT). However, the clinical value of such screening depends on precise prognostic predictions based on genotype-phenotype correlations and/or functional confirmation. We investigated familial hemophagocytic lymphohistiocytosis type 2 (FHL2), caused by PRF1 variants. Specifically, we evaluated the clinical significance of the frequent PRF1 A91V variant, if present in trans with a predicted loss-of-function (pLOF) PRF1 variant, defined as “disease mutation” listed in the Human Gene Mutation Database. We combined clinical and functional data from our hemophagocytic lymphohistiocytosis (HLH)–network registry with UK Biobank data to evaluate disease penetrance and clinical outcomes. Among 52 individuals with A91V/pLOF genotype in the registry, 39 (72%) showed FHL2-related manifestations with mean onset at 20 years. Four patients had recurrent disease, 15 received transplantation, and 14 died. Among 14 individuals with A91V/pLOF genotype identified by family screening (mean age, 29 years), however, only 1 was symptomatic. Moreover, among 21 A91V/pLOF carriers identified in 200 000 UK Biobank participants, 12 with genotypes identical to symptomatic registry patients, none had developed HLH by age 73 years. Premature stop pLOF alleles appeared more penetrant than missense variants, but functional data including perforin expression or cytotoxicity failed to predict disease manifestation. Our combined registry and population-based approach reveals significant variability in disease penetrance and severity among PRF1 A91V/pLOF carriers, with no clear association between genotype, functional data, and clinical outcomes. This complexity illustrates the challenges of genetic screening and highlights the need for careful clinical decision-making regarding preemptive HSCT in asymptomatic carriers.
- 19 June 2025
- Published by American Society of Hematology in Blood
- Vol. 145 (25) , 2992-3006
Open AccessBeyond genotype: challenges in predicting disease risk for carriers of biallelic perforin variants
Genetic screening for severe congenital immunohematological diseases offers potential for early intervention, particularly through preemptive allogeneic hematopoietic stem cell transplantation (HSCT). However, the clinical value of such screening depends on precise prognostic predictions based on genotype-phenotype correlations and/or functional confirmation. We investigated familial hemophagocytic lymphohistiocytosis type 2 (FHL2), caused by PRF1 variants. Specifically, we evaluated the clinical significance of the frequent PRF1 A91V variant, if present in trans with a predicted loss-of-function (pLOF) PRF1 variant, defined as “disease mutation” listed in the Human Gene Mutation Database. We combined clinical and functional data from our hemophagocytic lymphohistiocytosis (HLH)–network registry with UK Biobank data to evaluate disease penetrance and clinical outcomes. Among 52 individuals with A91V/pLOF genotype in the registry, 39 (72%) showed FHL2-related manifestations with mean onset at 20 years. Four patients had recurrent disease, 15 received transplantation, and 14 died. Among 14 individuals with A91V/pLOF genotype identified by family screening (mean age, 29 years), however, only 1 was symptomatic. Moreover, among 21 A91V/pLOF carriers identified in 200 000 UK Biobank participants, 12 with genotypes identical to symptomatic registry patients, none had developed HLH by age 73 years. Premature stop pLOF alleles appeared more penetrant than missense variants, but functional data including perforin expression or cytotoxicity failed to predict disease manifestation. Our combined registry and population-based approach reveals significant variability in disease penetrance and severity among PRF1 A91V/pLOF carriers, with no clear association between genotype, functional data, and clinical outcomes. This complexity illustrates the challenges of genetic screening and highlights the need for careful clinical decision-making regarding preemptive HSCT in asymptomatic carriers.
- Open Access
- 26 July 2024
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 44 (7) , 166
Genetic Testing in Patients with Autoimmune Lymphoproliferative Syndrome: Experience of 802 Patients at Cincinnati Children’s Hospital Medical Center
Autoimmune lymphoproliferative syndrome (ALPS) is a rare genetic disorder featuring chronic lymphadenopathy, splenomegaly, cytopenias, and increased lymphoma risk. Differentiating ALPS from immunodeficiencies with overlapping symptoms is challenging. This study evaluated the performance and the diagnostic yield of a 15-gene NGS panel for ALPS at Cincinnati Children’s Hospital Medical Center. Samples from 802 patients submitted for ALPS NGS panel were studied between May 2014 and January 2023. A total of 62 patients (7.7%) had a definite diagnosis: 52/62 cases (84%) showed 37 unique pathogenic/likely pathogenic germline FAS variants supporting ALPS diagnosis (6.5%, 52/802). The ALPS diagnostic yield increased to 30% in patients who additionally fulfilled abnormal ALPS immunology findings criteria. 17/37 (46%) diagnostic FAS variants were novel variants reported for the first time in ALPS. 10/802 cases (1.2%) showed diagnostic findings in five genes (ADA2, CTLA4, KRAS, MAGT1, NRAS) which are related to autoimmune lymphoproliferative immunodeficiency (ALPID). Family studies enabled the reclassification of variants of unknown significance (VUS) and also the identification of at-risk family members of FAS-positive patients, which helped in the follow-up diagnosis and treatment. Alongside family studies, complete clinical phenotypes and abnormal ALPS immunology and Fas-mediated apoptosis results helped clarify uncertain genetic findings. This study describes the largest cohort of genetic testing for suspected ALPS in North America and highlights the effectiveness of the ALPS NGS panel in distinguishing ALPS from non-ALPS immunodeficiencies. More comprehensive assessment from exome or genome sequencing could be considered for undefined ALPS-U patients or non-ALPS immunodeficiencies after weighing cost, completeness, and timeliness of different genetic testing options.
- 26 July 2024
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 44 (7) , 166
Open AccessGenetic Testing in Patients with Autoimmune Lymphoproliferative Syndrome: Experience of 802 Patients at Cincinnati Children’s Hospital Medical Center
Autoimmune lymphoproliferative syndrome (ALPS) is a rare genetic disorder featuring chronic lymphadenopathy, splenomegaly, cytopenias, and increased lymphoma risk. Differentiating ALPS from immunodeficiencies with overlapping symptoms is challenging. This study evaluated the performance and the diagnostic yield of a 15-gene NGS panel for ALPS at Cincinnati Children’s Hospital Medical Center. Samples from 802 patients submitted for ALPS NGS panel were studied between May 2014 and January 2023. A total of 62 patients (7.7%) had a definite diagnosis: 52/62 cases (84%) showed 37 unique pathogenic/likely pathogenic germline FAS variants supporting ALPS diagnosis (6.5%, 52/802). The ALPS diagnostic yield increased to 30% in patients who additionally fulfilled abnormal ALPS immunology findings criteria. 17/37 (46%) diagnostic FAS variants were novel variants reported for the first time in ALPS. 10/802 cases (1.2%) showed diagnostic findings in five genes (ADA2, CTLA4, KRAS, MAGT1, NRAS) which are related to autoimmune lymphoproliferative immunodeficiency (ALPID). Family studies enabled the reclassification of variants of unknown significance (VUS) and also the identification of at-risk family members of FAS-positive patients, which helped in the follow-up diagnosis and treatment. Alongside family studies, complete clinical phenotypes and abnormal ALPS immunology and Fas-mediated apoptosis results helped clarify uncertain genetic findings. This study describes the largest cohort of genetic testing for suspected ALPS in North America and highlights the effectiveness of the ALPS NGS panel in distinguishing ALPS from non-ALPS immunodeficiencies. More comprehensive assessment from exome or genome sequencing could be considered for undefined ALPS-U patients or non-ALPS immunodeficiencies after weighing cost, completeness, and timeliness of different genetic testing options.
- 3 December 2023
- Published by Elsevier in Genetics in Medicine
- Vol. 26 (3) , 101036
Recommendations for risk allele evidence curation, classification, and reporting from the ClinGen Low Penetrance/Risk Allele Working Group
- 3 December 2023
- Published by Elsevier in Genetics in Medicine
- Vol. 26 (3) , 101036
Recommendations for risk allele evidence curation, classification, and reporting from the ClinGen Low Penetrance/Risk Allele Working Group